The law under consideration “delinks” PBM compensation from manufacturer rebates in Medicare and requires flat administrative fees, certified at fair market value. It also mandates that rebates be passed through to health plan sponsors in the employer-sponsored market. This sounds appealing, but incentives matter. When compensation no longer depends on securing better terms, bargaining effort becomes a cost center rather than a profit center. PBMs will still compete for contracts, but competition on administrative fees isn’t the same as competition on aggressive price concessions and won’t lower drug prices.
03:19, 4 марта 2026Мир
。heLLoword翻译官方下载对此有专业解读
比起“瞒天过海”，更让人意外的是“精确斩首”。
中日關係再緊張：日本出招與那國島標誌防衛重心轉移，中國升級出口管制成效幾何
。业内人士推荐体育直播作为进阶阅读
[단독]“거부도 못해” 요양병원 ‘콧줄 환자’ 8만명。业内人士推荐下载安装 谷歌浏览器 开启极速安全的 上网之旅。作为进阶阅读
requestAnimationFrame